keyword
MENU ▼
Read by QxMD icon Read
search

HSDD

keyword
https://www.readbyqxmd.com/read/27916394/hypoactive-sexual-desire-disorder-international-society-for-the-study-of-women-s-sexual-health-isswsh-expert-consensus-panel-review
#1
REVIEW
Irwin Goldstein, Noel N Kim, Anita H Clayton, Leonard R DeRogatis, Annamaria Giraldi, Sharon J Parish, James Pfaus, James A Simon, Sheryl A Kingsberg, Cindy Meston, Stephen M Stahl, Kim Wallen, Roisin Worsley
The objective of the International Society for the Study of Women's Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels...
November 30, 2016: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/27916205/efficacy-and-safety-of-transdermal-testosterone-in-postmenopausal-women-with-hypoactive-sexual-desire-disorder-a-systematic-review-and-meta-analysis
#2
Chiara Achilli, Jyotsna Pundir, Parimalam Ramanathan, Luca Sabatini, Haitham Hamoda, Nick Panay
OBJECTIVE: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopausal women for the treatment of hypoactive sexual desire disorder (HSDD). DESIGN: Systematic reviews and meta-analysis. SETTING: Not applicable. PATIENT(S): Seven randomized controlled trials enrolled 3,035 participants; 1,350 women were randomized to treatment with T patch, and 1,379 women were randomized to placebo...
December 1, 2016: Fertility and Sterility
https://www.readbyqxmd.com/read/27872021/hypoactive-sexual-desire-disorder-a-review-of-epidemiology-biopsychology-diagnosis-and-treatment
#3
REVIEW
Sharon J Parish, Steven R Hahn
INTRODUCTION: Hypoactive Sexual Desire Disorder (HSDD) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-TR) as persistent deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), HSDD has been subsumed by Female Sexual Interest/Arousal Disorder. However, decades of research based on DSM-IV-TR HSDD criteria form the foundation of our understanding of the essential symptom of distressing low sexual desire, its epidemiology, clinical management, and treatment...
April 2016: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/27858170/flibanserin-and-its-discontents
#4
REVIEW
Awais Aftab, Cheryl Chen, Jacob McBride
In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This article summarizes and promotes discussion regarding the numerous controversies that have enclosed flibanserin since the very beginning. This includes questions related to flibanserin's safety and efficacy and the validity of the clinical trials. Also included are philosophical considerations surrounding the diagnosis of hypoactive sexual desire disorder and pharmacological treatment of low libido...
November 17, 2016: Archives of Women's Mental Health
https://www.readbyqxmd.com/read/27824686/hypoactive-sexual-desire-dysfunction-in-community-dwelling-older-women
#5
Berihun M Zeleke, Robin J Bell, Baki Billah, Susan R Davis
OBJECTIVE: To determine the prevalence of hypoactive sexual desire dysfunction (HSDD) and its associated factors in women aged 65 to 79 years. METHODS: A questionnaire-based, cross-sectional study was conducted amongst community-dwelling older women. Participants were recruited between April and August 2014 from a national database based on electoral rolls. Sexual function and sexual distress were assessed by the Female Sexual Function Index and the Female Sexual Distress Scale-Revised, respectively...
November 7, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27823751/female-sexual-dysfunction-fsd-prevalence-and-impact-on-quality-of-life-qol
#6
REVIEW
Prof Rossella E Nappi, Laura Cucinella, Silvia Martella, Margherita Rossi, Lara Tiranini, Ellis Martini
Female sexual dysfunction (FSD) and quality of life (QOL) are both multidimensional and have a bidirectional relationship across the reproductive life span and beyond. Methodological difficulties exist in estimating the real prevalence of FSD because it is hard to determine the level of distress associated with sexual symptoms in a large-scale survey. Approximately 40-50% of all women report at least one sexual symptom, and some conditions associated with hormonal changes at menopause, such as vulvovaginal atrophy (VVA) and hypoactive sexual desire disorder (HSDD), have a significant impact on sexual function and QOL...
December 2016: Maturitas
https://www.readbyqxmd.com/read/27784209/systematic-review-and-meta-analysis-of-flibanserin-s-effects-and-adverse-events-in-women-with-hypoactive-sexual-desire-disorder
#7
Amirhossein Sahebkar, Seyed Hassan Saadat, Yunes Panahi, Ali Kabir, Khaled Rahmani, Milad Hosseinialhashemi
The efficacy and safety of flibanserin in the treatment of Hypoactive Sexual Desire Disorder (HSDD) is controversial. We reviewed existing evidence on the efficacy and safety of flibanserin in treating HSDD, and performed a meta-analysis of reported effects. Literature search was performed on PubMed, Scopus, and Cochrane library to find all trials on the efficacy of flibanserin in HSDD. Meta-analysis was performed using fixed- and random-effects models. Egger's test and "trim and fill" methods were used for the assessment of publication bias and imputation of potentially missing studies, respectively...
October 25, 2016: Current Drug Metabolism
https://www.readbyqxmd.com/read/27663307/-efficacy-and-safety-of-flibanserin-new-female-viagra-%C3%A2-literature-review
#8
C Terrier, J-E Terrier
INTRODUCTION: In August 2015, the US Food and Drug Administration (FDA) has approved Addyi(®) (flibanserin) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in pre-menopausal women. We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in women with HSDD. PATIENTS AND METHODS: A systematic literature review from the PubMed database search was carried out until April 2016 using the following keywords: "HSDD", "flibanserin", "sexual desire" and "ransomised controlled trial"...
September 20, 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27649260/standards-in-studies-of-psychotherapy-and-pharmacotherapy-interventions-for-hsdd
#9
Anita Clayton, Robert Pyke
No abstract text is available yet for this article.
September 20, 2016: Journal of Sex & Marital Therapy
https://www.readbyqxmd.com/read/27592287/sexuality-and-quality-of-life-in-women-with-a-prior-diagnosis-of-breast-cancer-after-risk-reducing-salpingo-oophorectomy
#10
Paige E Tucker, Christobel Saunders, Max K Bulsara, Jason Jit-Sun Tan, Stuart G Salfinger, Helena Green, Paul A Cohen
OBJECTIVES: To investigate the prevalence of sexual dysfunction in women with a history of breast cancer following risk-reducing salpingo-oophorectomy (RRSO). A secondary objective was to examine the effect of a prior diagnosis of breast cancer, and other factors, on sexuality and quality of life (QoL) outcomes. STUDY DESIGN: Cross-sectional study of 119 women who underwent RRSO between 2009 and 2014. MAIN OUTCOME MEASURES: Data were collected via a questionnaire comprising demographic information and validated measures of sexual function, sexual distress, relationship satisfaction, body image, psychological stress, menopause symptoms and general quality of life...
December 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27287358/flibanserin-and-female-sexual-desire
#11
Heidi Collins Fantasia
Female hypoactive sexual desire disorder (HSDD) is one type of sexual problem that can affect women. It is characterized by low or absent sexual desire that cannot be attributed to another cause and results in difficulty in interpersonal relationships. HSDD is not well understood, and women may not report symptoms of difficulties to their health care providers. In August 2015, the U.S. Food and Drug Administration approved flibanserin, a nonhormonal oral medication for the treatment of HSDD in premenopausal women...
June 2016: Nursing for Women's Health
https://www.readbyqxmd.com/read/27260627/associations-of-body-mass-index-and-physical-activity-with-sexual-dysfunction-in-breast-cancer-survivors
#12
Carlos Eduardo Paiva, Fabiana Faria Rezende, Bianca Sakamoto Ribeiro Paiva, Edmundo Carvalho Mauad, Gustavo Zucca-Matthes, Estela Cristina Carneseca, Kari Juhani Syrjänen, Leslie R Schover
Sexual dysfunction is a common and distressing consequence of breast cancer (BC) treatment. In the present study, we investigated the sexual functioning of BC patients and its association with women's personal characteristics and cancer treatments. In this cross-sectional study, sexual function was assessed using the Female Sexual Function Index (FSFI). The health-related quality of life (HRQOL) was measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and its breast module BR-23...
June 3, 2016: Archives of Sexual Behavior
https://www.readbyqxmd.com/read/27152308/flibanserin-for-treating-hypoactive-sexual-desire-disorder
#13
REVIEW
Jae Hong Sang, Tae-Hee Kim, Soo Ah Kim
There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon...
April 2016: Journal of Menopausal Medicine
https://www.readbyqxmd.com/read/27149714/-testosterone-therapy-in-female-hypoactive-sexual-desire-disorder
#14
REVIEW
Patrick Meyer
Hypoactive sexual desire disorder (HSDD) is a deficiency of sexual desire that causes marked personal or interpersonal distress. It occurs in approximately 1 in 10 adult women. A number of potential contributory factors (hormonal, neurobiological and psychosocial) have been identified. Testosterone plays an excitatory role in sexual desire but the mechanism is not yet well understood. Treatment with testosterone has been shown to improve sexual desire in menopausal women with HSDD. However, there are limited data concerning premenopausal women and long-term safety...
March 16, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/27033339/acupuncture-in-premenopausal-women-with-hypoactive-sexual-desire-disorder-a-prospective-cohort-pilot-study
#15
Susan H Oakley, J Walther-Liu, C C Crisp, R N Pauls
INTRODUCTION: Female sexual dysfunction affects up to 43% of women in the United States and hypoactive sexual desire disorder (HSDD) is the most common type; however, we lack treatment options showing improvement for this condition. AIMS: To investigate whether acupuncture therapy could improve HSDD. METHODS: Premenopausal women with a primary diagnosis of HSDD were included in a single-arm prospective pilot study that was approved by the institutional review board...
September 2016: Sexual Medicine
https://www.readbyqxmd.com/read/26970346/anticipation-of-thermal-pain-in-diverticular-disease
#16
J K Smith, L Marciani, D J Humes, S T Francis, P Gowland, R C Spiller
BACKGROUND: The relative importance of peripheral nerve injury or central pain processing in painful diverticular disease (DD) is unclear. Functional magnetic resonance imaging (fMRI) has demonstrated that dysfunctional central pain processing predominates in irritable bowel syndrome (IBS). This study aims to identify anticipatory changes in symptomatic DD (SDD) compared to asymptomatic DD (ADD) and IBS patients. METHODS: Gastrointestinal symptoms and somatization were evaluated via the Patient Health Question-12 Somatic Symptom and the SDD group divided into low (≤6 [LSDD]) and high (≥7 [HSDD]) somatization...
June 2016: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/26927498/efficacy-and-safety-of-flibanserin-for-the-treatment-of-hypoactive-sexual-desire-disorder-in-women-a-systematic-review-and-meta-analysis
#17
REVIEW
Loes Jaspers, Frederik Feys, Wichor M Bramer, Oscar H Franco, Peter Leusink, Ellen T M Laan
IMPORTANCE: In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, despite concern about suboptimal risk-benefit trade-offs. OBJECTIVE: To conduct a systematic review and meta-analysis of randomized clinical trials assessing efficacy and safety of flibanserin for the treatment of HSDD in women. DATA SOURCES: Medical databases (among others, Embase, Medline, Psycinfo) and trial registries were searched from inception to June 17, 2015...
April 2016: JAMA Internal Medicine
https://www.readbyqxmd.com/read/26889096/biopsychosocial-determinants-of-hypoactive-sexual-desire-in-women-a-narrative-review
#18
Mina Malary, Soghra Khani, Mehdi Pourasghar, Mahmood Moosazadeh, Zeinab Hamzehgardeshi
BACKGROUND: As a mental response to sexual stimuli, sexual desire determines human sexual behavior and represents the cognitive capacity of sexual stimulation, so that avoiding sexual activity has a very negative effect on the discharge of intimacy and joy in couple's relationship and threatens the stability relationship, which can finally end in sexual dissatisfaction and divorce; it may even affect the reproduction. This study, reviews the literature on biopsychosocial determinants of hypoactive sexual desire disorder in women in childbearing ages...
December 2015: Materia Socio-medica
https://www.readbyqxmd.com/read/26873507/flibanserin-a-novel-nonhormonal-agent-for-the-treatment-of-hypoactive-sexual-desire-disorder-in-premenopausal-women
#19
Ximena Vallejos, Christine Wu
OBJECTIVE: To review pivotal clinical trials, pharmacology, contraindications, precautions, and key patient education points of flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. DATA SOURCES: A literature search of PubMed using the key words flibanserin and HSDD was conducted in September 2015. There was no time frame to exclude relevant clinical trials. All trials referenced were published between March 2012 and June 2014...
February 11, 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/26745616/efficacy-and-safety-of-flibanserin-in-women-with-hypoactive-sexual-desire-disorder-a-systematic-review-and-meta-analysis
#20
REVIEW
Zhenli Gao, Diandong Yang, Luxin Yu, Yuanshan Cui
INTRODUCTION: Flibanserin, is a postsynaptic agonist of serotonin receptor 1A and an antagonist of serotonin receptor 2A, has been shown to increase sexual desire and reduce distress in women with hypoactive sexual desire disorder (HSDD). AIM: We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in women with HSDD. METHODS: A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of flibanserin for the treatment of HSDD...
November 2015: Journal of Sexual Medicine
keyword
keyword
114579
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"